Follistatin-like 1 and its paralogs in heart development and cardiovascular disease
- 22 July 2022
- journal article
- research article
- Published by Springer Nature in Heart Failure Reviews
- Vol. 27 (6) , 2251-2265
Abstract
Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels and a leading cause of death worldwide. Thus, there is a need to identify new cardiokines that may protect the heart from damage as reported in GBD 2017 Causes of Death Collaborators (2018) (The Lancet 392:1736–1788). Follistatin-like 1 (FSTL1) is a cardiokine that is highly expressed in the heart and released to the serum after cardiac injury where it is associated with CVD and predicts poor outcome. The action of FSTL1 likely depends not only on the tissue source but also post-translation modifications that are target tissue- and cell-specific. Animal studies examining the effect of FSTL1 in various models of heart disease have exploded over the past 15 years and primarily report a protective effect spanning from inhibiting inflammation via transforming growth factor, preventing remodeling and fibrosis to promoting angiogenesis and hypertrophy. A better understanding of FSTL1 and its homologs is needed to determine whether this protein could be a useful novel biomarker to predict poor outcome and death and whether it has therapeutic potential. The aim of this review is to provide a comprehensive description of the literature for this family of proteins in order to better understand their role in normal physiology and CVD.Keywords
Funding Information
- NIH (R21 AI145356, R21 AI152318, R21 AI154927)
- American Heart Association (20TPA35490415)
- Ministerstvo Zdravotnictví Ceské Republiky (NU22-02-00418)
- Ministerstvo Školství, Mládeže a Tělovýchovy (LM2018121, CZ.02.1.01/0.0/0.0/17_04369/ 0009632, CZ.02.1.01/0.0/0.0/15_003/ 0000469)
This publication has 133 references indexed in Scilit:
- PaxDb, a Database of Protein Abundance Averages Across All Three Domains of LifeMolecular & Cellular Proteomics, 2012
- Diverse biological functions of the SPARC family of proteinsThe International Journal of Biochemistry & Cell Biology, 2012
- Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overloadProceedings of the National Academy of Sciences, 2011
- Follistatin-like 1 (Fstl1) is a bone morphogenetic protein (BMP) 4 signaling antagonist in controlling mouse lung developmentProceedings of the National Academy of Sciences, 2011
- The cardiokine story unfolds: ischemic stress-induced protein secretion in the heartTrends in Molecular Medicine, 2011
- Cardiac Myocyte-specific Ablation of Follistatin-like 3 Attenuates Stress-induced Myocardial HypertrophyJournal of Biological Chemistry, 2011
- Follistatin‐like protein 1 is a mesenchyme‐derived inflammatory protein and may represent a biomarker for systemic‐onset juvenile rheumatoid arthritisArthritis & Rheumatism, 2010
- Downregulated expression of the secreted glycoprotein follistatin-like 1 (Fstl1) is a robust hallmark of preadipocyte to adipocyte conversionMechanisms of Development, 2010
- DIP2A Functions as a FSTL1 ReceptorJournal of Biological Chemistry, 2010
- Follistatin-like 1, a Secreted Muscle Protein, Promotes Endothelial Cell Function and Revascularization in Ischemic Tissue through a Nitric-oxide Synthase-dependent MechanismJournal of Biological Chemistry, 2008